Improving quality of life in patients with metastatic prostate cancer following one cycle of177Lu-PSMA-617 radioligand therapy: a pilot study
- 1 December 2020
- journal article
- research article
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 59 (06), 409-414
- https://doi.org/10.1055/a-1234-5891
Abstract
Introduction To evaluate the clinical therapeutic response of PSMA targeted radioligand therapy with(177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. The current study analyzed disease-related quality of life (QoL) in patients undergoing PSMA therapy with a special focus on the association with simultaneous PSA response. Methods Thirty patients (age range 50-87 years, median 73.5 years) undergoing(177)Lu-PSMA-617 therapy from 2014 to 2016 at our institution were included in this pilot study. Health-related QoL was assessed by EORTC QLQ-C30 questionnaire filled in at baseline and two months after initializing the PSMA-therapy. The treatment response was evaluated under three categories with regard to changes in (a) global health status and other functional scales, (b) disease-related symptoms, and (c) effects of PSA values. Results Most patients underwent three treatment cycles (n = 12); at least 2 cycles (n = 6) or at most 8 cycles (n = 1) were performed. Out of 30 cases, PSA response after the first cycle was observed in 73 % (n = 22). Compared to baseline, QoL was significantly improved at 2-month follow-up revealing increase in global health status (p = 0.025), role functioning (p = 0.017) and emotional functioning (0.010), and decrease in pain (p = 0.033). Global health status variation can be explained up to 20.5 % by response in PSA (p = 0.012), this improved with PSA reduction. Conclusion PSMA radioligand therapy seems to be an effective treatment option of metastatic castration-resistant prostate cancer patients as it improves their QoL in terms of increasing global health and mitigation of disease-related pain.Keywords
This publication has 24 references indexed in Scilit:
- Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancerOncotarget, 2016
- Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617Journal of Nuclear Medicine, 2016
- 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessmentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- Improved quality of life is the way to longer lifeThe Lancet Oncology, 2016
- Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancerOncotarget, 2016
- Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre studyEJNMMI Research, 2015
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Interpreting quality of life dataEuropean Journal of Cancer, 2001
- The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30Quality of Life Research, 1996
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993